Home › Companies › Enliven Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Enliven Therapeutics, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 9, 2026: 5 items on Enliven Therapeutics, Inc.’s Form 8-K, filed June 10, 2026: 2 elected · 3 approved.
Significant dissent: 1 director (35.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2025-2026
Explore Enliven Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Enliven Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard Fair, M.B.A. | 50,534,439 | -- | -- | 152,188 | 5,452,158 | 99.7% | Elected | — |
| Elect Director: Lori Kunkel, M.D. | 32,788,330 | -- | -- | 17,898,297 | 5,452,158 | 65% | Elected | — |
| 2. Ratification of the Appointment of Independent Registered Public Accounting Firm | 56,119,493 | 795 | 18,497 | -- | 0 | 99.9% | Approved | — |
| 3. Amendment to the Amended and Restated Certificate of Incorporation, as Amended, to Increase the Company's Authorized Shares of Common Stock from 100,000,000 Shares to 200,000,000 Shares | 54,711,846 | 373,215 | 1,053,724 | -- | 0 | 99.3% | Approved | — |
| 4. Approval, in an Advisory (Non-binding) Vote, the Compensation of the Company's Named Executive Officers as Disclosed in the Proxy Statement | 47,572,153 | 3,093,447 | 21,027 | -- | 5,452,158 | 94% | Approved | — |
Source: Enliven Therapeutics, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
189 asset managers disclosed a vote on at least one Enliven Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Enliven Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
65% Majority: yes · of votes cast
Description as filed by funds: To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Lori Kunkel, M.D.
Enliven Therapeutics, Inc.’s own tally for this item (“Elect Director: Lori Kunkel, M.D.”): 32,788,330 for, 17,898,297 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class III Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders or until their successor is duly elected and qualified or until their earlier death, resignation or removal.”
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 8,893,647 for, 3,600,689 withheld, 33 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,139,759 | 0 | 0 | 0 | For |
| Vanguard | 8,980 | 0 | 33 | 2,467,165 | Withhold |
| BlackRock | 1,729,125 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 409,917 | Withhold |
| Charles Schwab | 361,117 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 227,320 | Withhold |
| Prudential/PGIM | 137,439 | 0 | 0 | 41,726 | Mixed |
| Principal | 0 | 0 | 0 | 92,547 | Withhold |
| T. Rowe Price | 92,002 | 0 | 0 | 0 | For |
| Equitable | 63,422 | 0 | 0 | 24,890 | Mixed |
| State Street | 80 | 0 | 0 | 81,423 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 60,923 | 0 | 0 | 0 | For |
| TIAA | 56,406 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 54,438 | Withhold |
| Tema ETF Trust | 49,589 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 45,551 | Withhold |
| Neuberger Berman | 39,632 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 36,149 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 24,160 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 20,685 | Withhold |
| Global X | 18,631 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 0 | 17,488 | Withhold |
| ProShares | 0 | 0 | 0 | 15,638 | Withhold |
| Advisor Managed Portfolios | 15,055 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 13,764 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Richard Fair, M.B.A.
Enliven Therapeutics, Inc.’s own tally for this item (“Elect Director: Richard Fair, M.B.A.”): 50,534,439 for, 152,188 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class III Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders or until their successor is duly elected and qualified or until their earlier death, resignation or removal.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 12,476,873 for, 17,497 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,139,759 | 0 | 0 | 0 | For |
| Vanguard | 2,476,178 | 0 | 0 | 0 | For |
| BlackRock | 1,729,125 | 0 | 0 | 0 | For |
| AllianceBernstein | 409,917 | 0 | 0 | 0 | For |
| Charles Schwab | 361,117 | 0 | 0 | 0 | For |
| Dimensional | 227,320 | 0 | 0 | 0 | For |
| Prudential/PGIM | 179,165 | 0 | 0 | 0 | For |
| Principal | 92,547 | 0 | 0 | 0 | For |
| T. Rowe Price | 92,002 | 0 | 0 | 0 | For |
| Equitable | 88,312 | 0 | 0 | 0 | For |
| State Street | 81,494 | 0 | 0 | 9 | For |
| QUANTITATIVE MASTER SERIES LLC | 60,923 | 0 | 0 | 0 | For |
| TIAA | 56,406 | 0 | 0 | 0 | For |
| American Century | 54,438 | 0 | 0 | 0 | For |
| Tema ETF Trust | 49,589 | 0 | 0 | 0 | For |
| Lincoln Financial | 45,551 | 0 | 0 | 0 | For |
| Neuberger Berman | 39,632 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 36,149 | 0 | 0 | 0 | For |
| Northern Trust | 24,160 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,685 | 0 | 0 | 0 | For |
| Global X | 18,631 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 0 | 17,488 | Withhold |
| ProShares | 15,638 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 15,055 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 13,764 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
99.3% Approved · of votes cast
Description as filed by funds: To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.
Enliven Therapeutics, Inc.’s own tally for this item (“3. Amendment to the Amended and Restated Certificate of Incorporation, as Amended, to Increase the Company's Authorized Shares of Common Stock from 100,000,000 Shares to 200,000,000 Shares”): 54,711,846 for, 373,215 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to the Amended and Restated Certificate of Incorporation, as amended, to increase the Company's authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 12,460,917 for, 33,449 against, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,139,759 | 0 | 0 | 0 | For |
| Vanguard | 2,472,309 | 3,866 | 3 | 0 | For |
| BlackRock | 1,729,125 | 0 | 0 | 0 | For |
| AllianceBernstein | 409,917 | 0 | 0 | 0 | For |
| Charles Schwab | 361,117 | 0 | 0 | 0 | For |
| Dimensional | 227,320 | 0 | 0 | 0 | For |
| Prudential/PGIM | 167,365 | 11,800 | 0 | 0 | Mixed |
| Principal | 92,547 | 0 | 0 | 0 | For |
| T. Rowe Price | 92,002 | 0 | 0 | 0 | For |
| Equitable | 88,312 | 0 | 0 | 0 | For |
| State Street | 81,473 | 30 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 60,923 | 0 | 0 | 0 | For |
| TIAA | 56,406 | 0 | 0 | 0 | For |
| American Century | 54,438 | 0 | 0 | 0 | For |
| Tema ETF Trust | 49,589 | 0 | 0 | 0 | For |
| Lincoln Financial | 45,551 | 0 | 0 | 0 | For |
| Neuberger Berman | 39,632 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 35,883 | 266 | 0 | 0 | For |
| Northern Trust | 24,160 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,685 | 0 | 0 | 0 | For |
| Global X | 18,631 | 0 | 0 | 0 | For |
| AuguStar | 0 | 17,488 | 0 | 0 | Against |
| ProShares | 15,638 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 15,055 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 13,764 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: To approve, in an advisory (non- binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.
Enliven Therapeutics, Inc.’s own tally for this item (“4. Approval, in an Advisory (Non-binding) Vote, the Compensation of the Company's Named Executive Officers as Disclosed in the Proxy Statement”): 47,572,153 for, 3,093,447 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, in an advisory (non-binding) vote, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,139,759 | 0 | 0 | 0 | For |
| Vanguard | 2,470,406 | 5,771 | 0 | 0 | For |
| BlackRock | 1,729,125 | 0 | 0 | 0 | For |
| AllianceBernstein | 409,917 | 0 | 0 | 0 | For |
| Charles Schwab | 361,117 | 0 | 0 | 0 | For |
| Dimensional | 0 | 227,320 | 0 | 0 | Against |
| Prudential/PGIM | 166,954 | 12,211 | 0 | 0 | Mixed |
| Principal | 92,547 | 0 | 0 | 0 | For |
| T. Rowe Price | 92,002 | 0 | 0 | 0 | For |
| Equitable | 88,312 | 0 | 0 | 0 | For |
| State Street | 81,480 | 23 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 60,923 | 0 | 0 | 0 | For |
| TIAA | 56,406 | 0 | 0 | 0 | For |
| American Century | 0 | 54,438 | 0 | 0 | Against |
| Tema ETF Trust | 49,589 | 0 | 0 | 0 | For |
| Lincoln Financial | 45,551 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 39,632 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 36,149 | 0 | 0 | Against |
| Northern Trust | 0 | 24,160 | 0 | 0 | Against |
| AIG/SunAmerica | 20,685 | 0 | 0 | 0 | For |
| Global X | 0 | 18,631 | 0 | 0 | Against |
| AuguStar | 0 | 0 | 17,488 | 0 | Abstain |
| ProShares | 15,638 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 15,055 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 13,764 | 0 | 0 | 0 | For |
Fund voting reports, all 57 managers: 12,022,938 for, 453,944 against, 17,488 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 9,884,336 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 7,957,413 | 0 | 0 | 0 | For |
| Fidelity | 5,303,610 | 0 | 0 | 0 | For |
| Commodore Capital LP | 2,410,000 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 2,356,333 | 0 | 0 | 0 | For |
| Fairmount Funds Management LLC | 1,855,644 | 0 | 0 | 0 | For |
| BlackRock | 1,401,437 | 5,935 | 0 | 0 | For |
| Novo Holdings A/S | 1,200,000 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 1,175,672 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,032,559 | 0 | 0 | 0 | For |
| Citadel | 1,010,529 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 929,280 | 0 | 0 | 0 | For |
| State Street | 867,970 | 2,157 | 0 | 0 | For |
| Rock Springs Capital Management LP | 808,095 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 746,226 | 0 | 0 | 0 | For |
| AllianceBernstein | 740,321 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 594,079 | 0 | 0 | Against |
| Affinity Asset Advisors, LLC | 418,519 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 0 | 400,000 | 0 | 0 | Against |
| Charles Schwab | 366,956 | 0 | 0 | 0 | For |
| Vanguard | 362,144 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 343,559 | 0 | 0 | 0 | For |
| Woodline Partners LP | 330,515 | 0 | 0 | 0 | For |
| Northern Trust | 10,675 | 236,624 | 0 | 0 | Against |
| ADAR1 Capital Management, LLC | 240,460 | 0 | 0 | 0 | For |
Institutional-manager reports, all 149 managers: 43,622,487 for, 2,374,113 against, 705 abstained, 11,964 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve, in an advisory (non- binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
| Principal | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| Tema ETF Trust | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 20,151 | 0 | 0 | 0 | For |
| Neuberger Berman | 0 | 0 | 0 | 0 | -- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| AuguStar | 0 | 0 | 17,488 | 0 | Abstain |
| ProShares | 0 | 0 | 0 | 0 | -- |
| Advisor Managed Portfolios | 0 | 0 | 0 | 0 | -- |
| Franklin Alternative Strategies Funds | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 57 managers: 32,653 for, 17,488 abstained, 12,200,897 1 year, 243,238 3 year, 94 unknown. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 0 | 0 | 0 | 0 | -- |
| ORBIMED ADVISORS LLC | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Commodore Capital LP | 0 | 0 | 0 | 0 | -- |
| Vestal Point Capital, LP | 0 | 0 | 0 | 0 | -- |
| Fairmount Funds Management LLC | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Novo Holdings A/S | 0 | 0 | 0 | 0 | -- |
| Venrock Adviser, LLC | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| PICTET ASSET MANAGEMENT SA | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Rock Springs Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Siren, L.L.C. | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Candriam S.C.A. | 0 | 0 | 0 | 0 | -- |
| Affinity Asset Advisors, LLC | 0 | 0 | 0 | 0 | -- |
| Avidity Partners Management LP | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| First Light Asset Management, LLC | 343,559 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| ADAR1 Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| Logos Global Management LP | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 146 managers: 683,501 for, 194 against, 45,049,036 1 year, 70,973 3 year. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 100.0% for (June 24, 2025 meeting) unchanged
Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.
Enliven Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 56,119,493 for, 795 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 12,476,882 for, 17,488 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,139,759 | 0 | 0 | 0 | For |
| Vanguard | 2,476,178 | 0 | 0 | 0 | For |
| BlackRock | 1,729,125 | 0 | 0 | 0 | For |
| AllianceBernstein | 409,917 | 0 | 0 | 0 | For |
| Charles Schwab | 361,117 | 0 | 0 | 0 | For |
| Dimensional | 227,320 | 0 | 0 | 0 | For |
| Prudential/PGIM | 179,165 | 0 | 0 | 0 | For |
| Principal | 92,547 | 0 | 0 | 0 | For |
| T. Rowe Price | 92,002 | 0 | 0 | 0 | For |
| Equitable | 88,312 | 0 | 0 | 0 | For |
| State Street | 81,503 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 60,923 | 0 | 0 | 0 | For |
| TIAA | 56,406 | 0 | 0 | 0 | For |
| American Century | 54,438 | 0 | 0 | 0 | For |
| Tema ETF Trust | 49,589 | 0 | 0 | 0 | For |
| Lincoln Financial | 45,551 | 0 | 0 | 0 | For |
| Neuberger Berman | 39,632 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 36,149 | 0 | 0 | 0 | For |
| Northern Trust | 24,160 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,685 | 0 | 0 | 0 | For |
| Global X | 18,631 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 17,488 | 0 | Abstain |
| ProShares | 15,638 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 15,055 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 13,764 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,889,655 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 10.08% |
| 2 | Vanguard | 4.07% |
| 3 | BlackRock | 2.84% |
| 4 | AllianceBernstein | 0.67% |
| 5 | Charles Schwab | 0.59% |
| 6 | Dimensional | 0.37% |
| 7 | Prudential/PGIM | 0.29% |
| 8 | Principal | 0.15% |
| 9 | T. Rowe Price | 0.15% |
| 10 | Equitable | 0.15% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Polar Capital Holdings Plc | 16.23% |
| 2 | ORBIMED ADVISORS LLC | 13.07% |
| 3 | Fidelity | 8.71% |
| 4 | Commodore Capital LP | 3.96% |
| 5 | Vestal Point Capital, LP | 3.87% |
| 6 | Fairmount Funds Management LLC | 3.05% |
| 7 | BlackRock | 2.31% |
| 8 | Novo Holdings A/S | 1.97% |
| 9 | Venrock Adviser, LLC | 1.93% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.70% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Entities affiliated with OrbiMed Advisors LLC | 7,959,538 | 13.07% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| Entities affiliated with FMR LLC | 7,870,219 | 12.93% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| FMR (Fidelity) | 6,829,246 | 11.22% | Form 13F, quarter ended March 31, 2026 |
| Polar Capital Holdings Plc | 5,056,807 | 8.30% | Schedule 13G, filed June 22, 2026 |
| Commodore Capital LP | 4,800,940 | 7.88% | Schedule 13G, filed May 15, 2026 |
| Fairmount Healthcare Fund II LP | 3,711,444 | 6.10% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| BlackRock | 3,684,707 | 6.05% | Form 13F, quarter ended March 31, 2026 |
| Vestal Point Capital, LP | 3,250,000 | 5.34% | Schedule 13G, filed May 15, 2026 |
| Entities affiliated with Venrock Healthcare Capital Partners | 3,226,331 | 5.30% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| Vanguard Group | 2,801,665 | 4.60% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 60,889,655 shares outstanding, as reported by Enliven Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Enliven Therapeutics, Inc.'s shareholder meeting held June 9, 2026, in the 2025-2026 proxy season, 189 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,638 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, in an advisory (non- binding) vote, the compensation of our named executive… — Enliven Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Enliven Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Enliven Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Enliven Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
Proxy Votes Now, “Enliven Therapeutics (ELVN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/enliven-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.